Study of repotrectinib for older or frail patients with ROS1-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an oral targeted therapy called repotrectinib in people with advanced non-small cell lung cancer (NSCLC) that has a change in the ROS1 gene. It is designed for patients who are either 70 or older, or have a lower performance status (ECOG 2 or higher), meaning they may be more frail or have more symptoms. The goal is to see if repotrectinib can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced non-small cell lung cancer with a change in the ROS1 gene.
- You are either 70 years or older, or your doctor rates your daily activity level as 2 or higher on a scale called ECOG (meaning you need more help with daily tasks).
- You must have at least one tumor that can be measured on a scan (like a CT or MRI).
- If you have had chemotherapy or immunotherapy before, a brief waiting period is needed before starting repotrectinib.
- If you have never had a ROS1-targeted drug before, you can join; if you have had one, only some patients qualify.
- You must have adequate kidney, liver, and blood cell counts as determined by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial tests a new targeted therapy pill (repotrectinib) for people with ROS1-positive lung cancer that has spread to the brain. The pill is designed to enter the brain and attack cancer cells that other targeted treatments may not reach well.
This study tracks how well and safely repotrectinib (a targeted cancer drug) works in Korean patients with specific types of lung cancer or solid tumors. You'd be monitored after starting this medication to help doctors understand how it affects people over time.
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
This trial studies repotrectinib, a targeted medicine, in people with advanced solid tumors that have specific gene rearrangements (ALK, ROS1, or NTRK). It may help shrink tumors or control cancer growth based on the patient’s tumor genetic result.
This Phase 1 trial tests how safe and effective repotrectinib plus osimertinib are for people with advanced or metastatic non-squamous lung cancer with specific EGFR mutations. It may help shrink tumors when surgery or radiation can’t cure the cancer, including in some cases after osimertinib or other EGFR pills.
This study looks at how well the drug taletrectinib works for people with a specific type of advanced lung cancer (ROS1-positive NSCLC) whose cancer has gotten worse after treatment with the drug entrectinib. It aims to help doctors understand real-world outcomes for these patients.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.